IL13Ra2

ImmunoCellular Therapeutics Announces Licensing Agreement with Targepeutics for Worldwide Intellectual Property Rights to Validated Immunotherapy Target
Tue, 06/22/10 - 12:57 pm
ImmunoCellular Therapeutics
Targepeutics
glioblastoma multiforme
brain cancer
IL13Ra2